[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Linagliptin.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Linagliptin.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be decreased when combined with Linagliptin.]
[B01AD01, streptokinase, The risk or severity of angioedema can be increased when Streptokinase is combined with Linagliptin.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Linagliptin.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Linagliptin.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Sulfinpyrazone can be decreased when combined with Linagliptin.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Sulfisoxazole is combined with Linagliptin.]
[A10BB04, glibornuride, Linagliptin may increase the hypoglycemic activities of Glibornuride.]
[A10BC01, glymidine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Glymidine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Linagliptin.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Linagliptin.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Linagliptin.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Linagliptin.]
[S03AA02, tetracycline, The metabolism of Tetracycline can be decreased when combined with Linagliptin.]
[N05AE05, lurasidone, The metabolism of Lurasidone can be decreased when combined with Linagliptin.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Linagliptin.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Linagliptin.]
[A11DA01, thiamine, The serum concentration of Linagliptin can be increased when it is combined with Thiamine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Linagliptin.]
[S01ED01, timolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Timolol.]
[P01AB02, tinidazole, The metabolism of Tinidazole can be decreased when combined with Linagliptin.]
[A10BB05, tolazamide, Linagliptin may increase the hypoglycemic activities of Tolazamide.]
[V04CA01, tolbutamide, Linagliptin may increase the hypoglycemic activities of Tolbutamide.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Linagliptin.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypoglycemic activities of Linagliptin.]
[N06AX05, trazodone, The serum concentration of Linagliptin can be decreased when it is combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Linagliptin.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Linagliptin.]
[N05CD05, triazolam, The metabolism of Triazolam can be decreased when combined with Linagliptin.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Trichlormethiazide.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Linagliptin.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Linagliptin.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Linagliptin.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Linagliptin.]
[A03AA05, trimebutine, The metabolism of Trimebutine can be decreased when combined with Linagliptin.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Linagliptin.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Linagliptin.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Linagliptin.]
[J01FA08, troleandomycin, The metabolism of Linagliptin can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Linagliptin.]
[C09CA09, azilsartan medoxomil, The risk or severity of angioedema can be increased when Azilsartan medoxomil is combined with Linagliptin.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Linagliptin is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Linagliptin.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Linagliptin.]
[L02BX03, abiraterone, The metabolism of Linagliptin can be decreased when combined with Abiraterone.]
[J05AP03, boceprevir, The metabolism of Linagliptin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Linagliptin can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Rilpivirine can be decreased when combined with Linagliptin.]
[B01AD04, urokinase, The risk or severity of angioedema can be increased when Urokinase is combined with Linagliptin.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Linagliptin.]
[R03AC18, indacaterol, The metabolism of Indacaterol can be decreased when combined with Linagliptin.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Linagliptin.]
[C08DA01, verapamil, The metabolism of Linagliptin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Linagliptin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Linagliptin.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Linagliptin.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Linagliptin.]
[A11HA03, vitamin E, The metabolism of Vitamin E can be decreased when combined with Linagliptin.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Linagliptin.]
[S01AA13, fusidic acid, The metabolism of Linagliptin can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, The therapeutic efficacy of Linagliptin can be increased when used in combination with Xipamide.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Linagliptin can be increased when used in combination with Pipemidic acid.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Linagliptin.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Linagliptin.]
[J05AE02, indinavir, The metabolism of Linagliptin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Linagliptin can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Linagliptin.]
[B06AC02, icatibant, The risk or severity of angioedema can be increased when Icatibant is combined with Linagliptin.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Linagliptin.]
[R03DC01, zafirlukast, The metabolism of Linagliptin can be decreased when combined with Zafirlukast.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Drospirenone.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Linagliptin.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Linagliptin.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Linagliptin.]
[C07AB03, atenolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Atenolol.]
[J02AC03, voriconazole, The metabolism of Linagliptin can be decreased when combined with Voriconazole.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Linagliptin.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Linagliptin.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Linagliptin.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Linagliptin.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Linagliptin.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Linagliptin.]
[M03BX01, baclofen, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Baclofen.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Linagliptin.]
[G04BD12, mirabegron, The metabolism of Mirabegron can be decreased when combined with Linagliptin.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Linagliptin.]
[V03AX03, cobicistat, The metabolism of Linagliptin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Linagliptin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Linagliptin can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Linagliptin.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Linagliptin.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Linagliptin.]
[N05CA04, barbital, The metabolism of Linagliptin can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Linagliptin can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Linagliptin.]
[N04BD02, rasagiline, Rasagiline may increase the hypoglycemic activities of Linagliptin.]
[C08CA13, lercanidipine, The metabolism of Lercanidipine can be decreased when combined with Linagliptin.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Linagliptin.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Linagliptin.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Linagliptin.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Linagliptin.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Linagliptin.]
[H01CB05, pasireotide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Linagliptin.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Linagliptin.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Linagliptin.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Linagliptin.]
[J04AK05, bedaquiline, The metabolism of Bedaquiline can be decreased when combined with Linagliptin.]
[C04AX11, bencyclane, The metabolism of Bencyclane can be decreased when combined with Linagliptin.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Linagliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Linagliptin can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Linagliptin.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Linagliptin.]
[A10BK02, canagliflozin, Canagliflozin may increase the hypoglycemic activities of Linagliptin.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Gemifloxacin.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Linagliptin.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Linagliptin.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin detemir.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Linagliptin.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Linagliptin.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Linagliptin.]
[L01EC02, dabrafenib, The serum concentration of Linagliptin can be decreased when it is combined with Dabrafenib.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Linagliptin.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Linagliptin.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Linagliptin.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Linagliptin.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Linagliptin.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Lixisenatide.]
[C02KX04, macitentan, The metabolism of Macitentan can be decreased when combined with Linagliptin.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Linagliptin.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Linagliptin.]
[G03AC08, etonogestrel, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etonogestrel.]
[N03AF04, eslicarbazepine, The metabolism of Linagliptin can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Linagliptin can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Linagliptin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Linagliptin.]
[C07AB04, acebutolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Linagliptin.]
[A16AA07, metreleptin, The metabolism of Linagliptin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Linagliptin can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Linagliptin can be increased when combined with Formestane.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Linagliptin.]
[S01ED02, betaxolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Betaxolol.]
[C10AB02, bezafibrate, The metabolism of Bezafibrate can be decreased when combined with Linagliptin.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Linagliptin can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Linagliptin.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Linagliptin.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Linagliptin.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Linagliptin.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Linagliptin.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Linagliptin.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Linagliptin.]
[J01XA05, oritavancin, The metabolism of Linagliptin can be increased when combined with Oritavancin.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Dulaglutide.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Linagliptin.]
[A11HA08, tocophersolan, The metabolism of Tocofersolan can be decreased when combined with Linagliptin.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Linagliptin.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Linagliptin.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Linagliptin.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Linagliptin.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Linagliptin.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be decreased when combined with Linagliptin.]
[L04AC10, secukinumab, The metabolism of Linagliptin can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Linagliptin.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Linagliptin.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Linagliptin.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Linagliptin.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Linagliptin.]
[C01EB17, ivabradine, The metabolism of Ivabradine can be decreased when combined with Linagliptin.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Linagliptin.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Linagliptin.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Linagliptin.]
[A04AD14, rolapitant, The metabolism of Rolapitant can be decreased when combined with Linagliptin.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Linagliptin.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Linagliptin.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Acarbose is combined with Linagliptin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Linagliptin can be increased when used in combination with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin degludec.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Linagliptin.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Linagliptin.]
[J02AC05, isavuconazole, The serum concentration of Linagliptin can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Linagliptin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Linagliptin.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Linagliptin.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Linagliptin.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Linagliptin.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Linagliptin.]
[A10BB31, acetohexamide, Linagliptin may increase the hypoglycemic activities of Acetohexamide.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Linagliptin.]
[M04AB05, lesinurad, The metabolism of Linagliptin can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Linagliptin.]
[J05AP11, grazoprevir, The metabolism of Grazoprevir can be decreased when combined with Linagliptin.]
[N05CA05, aprobarbital, The metabolism of Linagliptin can be increased when combined with Aprobarbital.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Linagliptin.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Linagliptin.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Linagliptin.]
[N04BC01, bromocriptine, The metabolism of Bromocriptine can be decreased when combined with Linagliptin.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Linagliptin.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Linagliptin.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be decreased when combined with Linagliptin.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Linagliptin.]
[C03CA02, bumetanide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Bumetanide.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be decreased when combined with Linagliptin.]
[C07AA19, bupranolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Linagliptin.]
[L02AE01, buserelin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Linagliptin.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Linagliptin.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Linagliptin.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sparfloxacin.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Linagliptin.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Linagliptin.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Linagliptin.]
[L01EF02, ribociclib, The metabolism of Linagliptin can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Linagliptin.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Linagliptin.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Linagliptin.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Linagliptin.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Benfluorex.]
[D05AX03, calcitriol, The metabolism of Calcitriol can be decreased when combined with Linagliptin.]
[J01XX08, linezolid, Linezolid may increase the hypoglycemic activities of Linagliptin.]
[J05AE09, tipranavir, The serum concentration of Linagliptin can be decreased when it is combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Linagliptin.]
[L04AB02, infliximab, The metabolism of Linagliptin can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Linagliptin can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Linagliptin.]
[N04BD03, safinamide, The metabolism of Safinamide can be decreased when combined with Linagliptin.]
[L04AC14, sarilumab, The metabolism of Linagliptin can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Delafloxacin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Linagliptin.]
[D01AC10, bifonazole, The metabolism of Linagliptin can be decreased when combined with Bifonazole.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Linagliptin is combined with Acetylcholine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Linagliptin.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Linagliptin.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Linagliptin.]
[L01XH01, vorinostat, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Linagliptin.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Linagliptin.]
[C07AB07, bisoprolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Linagliptin can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Bopindolol.]
[N05CD09, brotizolam, The metabolism of Brotizolam can be decreased when combined with Linagliptin.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Linagliptin.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Linagliptin.]
[J05AX18, letermovir, The metabolism of Linagliptin can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Linagliptin.]
[C01AA02, acetyldigoxins, Linagliptin may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Semaglutide.]
[N01BX04, capsaicin, The metabolism of Linagliptin can be decreased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Ertugliflozin.]
[C09AA01, captopril, The risk or severity of angioedema can be increased when Linagliptin is combined with Captopril.]
[V04CD06, macimorelin, The metabolism of Macimorelin can be decreased when combined with Linagliptin.]
[L02BB05, apalutamide, The serum concentration of Linagliptin can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Linagliptin.]
[C07AG02, carvedilol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Fostamatinib can be decreased when combined with Linagliptin.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Linagliptin.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Linagliptin.]
[L04AA37, baricitinib, The metabolism of Baricitinib can be decreased when combined with Linagliptin.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Linagliptin.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Linagliptin.]
[C07AB08, celiprolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Celiprolol.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Linagliptin.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be decreased when combined with Linagliptin.]
[P01BA07, tafenoquine, The serum concentration of Linagliptin can be increased when it is combined with Tafenoquine.]
[N03AX17, stiripentol, The metabolism of Linagliptin can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Linagliptin.]
[J05AX24, tecovirimat, The metabolism of Linagliptin can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Linagliptin.]
[J01AA13, eravacycline, The metabolism of Eravacycline can be decreased when combined with Linagliptin.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Linagliptin.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Linagliptin.]
[J01AA14, sarecycline, The serum concentration of Linagliptin can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Linagliptin.]
[A10BB06, carbutamide, Linagliptin may increase the hypoglycemic activities of Carbutamide.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Linagliptin.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Linagliptin.]
[L01ED05, lorlatinib, The serum concentration of Linagliptin can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Linagliptin can be increased when combined with Emapalumab.]
[L01EX12, larotrectinib, The metabolism of Larotrectinib can be decreased when combined with Linagliptin.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Linagliptin.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Linagliptin.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Linagliptin.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Linagliptin.]
[C09AA08, cilazapril, The risk or severity of angioedema can be increased when Linagliptin is combined with Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Linagliptin.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Linagliptin.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Linagliptin.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Linagliptin is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Linagliptin can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The serum concentration of Solriamfetol can be increased when it is combined with Linagliptin.]
[L01EN01, erdafitinib, The serum concentration of Linagliptin can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The metabolism of Clobazam can be decreased when combined with Linagliptin.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Linagliptin.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Linagliptin.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Linagliptin.]
[L04AB01, etanercept, The metabolism of Linagliptin can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Linagliptin.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Linagliptin.]
[L01FX14, polatuzumab vedotin, The metabolism of Polatuzumab vedotin can be decreased when combined with Linagliptin.]
[L01XX66, selinexor, The metabolism of Selinexor can be decreased when combined with Linagliptin.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be decreased when combined with Linagliptin.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Linagliptin.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Linagliptin.]
[L04AA44, upadacitinib, The metabolism of Upadacitinib can be decreased when combined with Linagliptin.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Linagliptin.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Linagliptin.]
[N07XX11, pitolisant, The serum concentration of Linagliptin can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The serum concentration of Pretomanid can be increased when it is combined with Linagliptin.]
[J01XX12, lefamulin, Linagliptin may decrease the excretion rate of Lefamulin which could result in a higher serum level.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Linagliptin.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Linagliptin.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin pork.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Linagliptin.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Linagliptin.]
[J01DB09, cephradine, The metabolism of Linagliptin can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Linagliptin.]
[G03DB05, demegestone, The metabolism of Demegestone can be decreased when combined with Linagliptin.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Linagliptin.]
[N02CC08, lasmiditan, The serum concentration of Linagliptin can be increased when it is combined with Lasmiditan.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Linagliptin.]
[G03AC09, desogestrel, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Linagliptin.]
[N03AX25, cenobamate, The serum concentration of Linagliptin can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Linagliptin.]
[L01FX13, enfortumab vedotin, The metabolism of Enfortumab vedotin can be decreased when combined with Linagliptin.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Linagliptin.]
[N05CM21, lemborexant, The metabolism of Lemborexant can be decreased when combined with Linagliptin.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Linagliptin.]
[L04AA53, teprotumumab, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Teprotumumab.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Linagliptin.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Linagliptin.]
[J05AB16, remdesivir, The metabolism of Remdesivir can be decreased when combined with Linagliptin.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Osilodrostat can be decreased when combined with Linagliptin.]
[J05AE05, amprenavir, The metabolism of Linagliptin can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Linagliptin.]
[G03DB08, dienogest, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Linagliptin.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Linagliptin.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Linagliptin.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Linagliptin.]
[L01XF03, bexarotene, The metabolism of Linagliptin can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Linagliptin.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Linagliptin.]
[J01FA13, dirithromycin, The metabolism of Linagliptin can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Linagliptin can be decreased when combined with Chloramphenicol.]
[L01EN02, pemigatinib, The metabolism of Pemigatinib can be decreased when combined with Linagliptin.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Linagliptin which could result in a higher serum level.]
[L01EX17, capmatinib, The metabolism of Capmatinib can be decreased when combined with Linagliptin.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Linagliptin.]
[L01EX19, ripretinib, The metabolism of Ripretinib can be decreased when combined with Linagliptin.]
[L01EX22, selpercatinib, The metabolism of Selpercatinib can be decreased when combined with Linagliptin.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Linagliptin.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Linagliptin.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be increased when it is combined with Linagliptin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Linagliptin.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Linagliptin.]
[J05AX29, fostemsavir, The metabolism of Fostemsavir can be decreased when combined with Linagliptin.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Linagliptin.]
[L04AC19, satralizumab, The serum concentration of Linagliptin can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be increased when it is combined with Linagliptin.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Linagliptin.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Linagliptin.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Linagliptin.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, Linagliptin may increase the hypoglycemic activities of Chlorpropamide.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Linagliptin.]
[A11CC05, cholecalciferol, The metabolism of Cholecalciferol can be decreased when combined with Linagliptin.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Linagliptin.]
[N06BX18, vinpocetine, The metabolism of Vinpocetine can be decreased when combined with Linagliptin.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be decreased when combined with Linagliptin.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Linagliptin.]
[A16AX20, lonafarnib, The metabolism of Linagliptin can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Linagliptin.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be decreased when combined with Linagliptin.]
[P03AX07, abametapir, The serum concentration of Linagliptin can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Linagliptin.]
[L01EX25, umbralisib, The serum concentration of Linagliptin can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Linagliptin.]
[N03AX10, felbamate, The metabolism of Felbamate can be decreased when combined with Linagliptin.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Linagliptin.]
[J01MB07, flumequine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Linagliptin.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Linagliptin.]
[R03CC15, formoterol, The risk or severity of adverse effects can be increased when Linagliptin is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin human.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be decreased when combined with Linagliptin.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Linagliptin.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Linagliptin.]
[A02BA01, cimetidine, The serum concentration of Linagliptin can be increased when it is combined with Cimetidine.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Linagliptin.]
[J01MB06, cinoxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Linagliptin can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Linagliptin.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Ciprofloxacin.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Linagliptin.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Linagliptin.]
[H01AC07, somapacitan, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Somapacitan.]
[J02AX07, ibrexafungerp, The metabolism of Ibrexafungerp can be decreased when combined with Linagliptin.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Linagliptin.]
[L04AA48, belumosudil, The metabolism of Belumosudil can be decreased when combined with Linagliptin.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Linagliptin.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lonapegsomatropin.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be decreased when combined with Linagliptin.]
[L01FX23, tisotumab vedotin, The metabolism of Tisotumab vedotin can be decreased when combined with Linagliptin.]
[N02CD07, atogepant, The metabolism of Atogepant can be decreased when combined with Linagliptin.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Linagliptin.]
[L04AA59, avacopan, The metabolism of Avacopan can be decreased when combined with Linagliptin.]
[A10BB12, glimepiride, Linagliptin may increase the hypoglycemic activities of Glimepiride.]
[A10BB08, gliquidone, Linagliptin may increase the hypoglycemic activities of Gliquidone.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Linagliptin.]
[N06AX25, St. John's wort extract, The serum concentration of Linagliptin can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Linagliptin can be increased when it is combined with Asciminib.]
[L02BG06, exemestane, The metabolism of Exemestane can be decreased when combined with Linagliptin.]
[J05AX10, maribavir, The metabolism of Maribavir can be decreased when combined with Linagliptin.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Linagliptin.]
[D11AH08, abrocitinib, The serum concentration of Linagliptin can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Linagliptin can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of angioedema can be increased when Tenecteplase is combined with Linagliptin.]
[C10AB01, clofibrate, The metabolism of Clofibrate can be decreased when combined with Linagliptin.]
[B06AX04, mitapivat, The metabolism of Mitapivat can be decreased when combined with Linagliptin.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be increased when it is combined with Linagliptin.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Linagliptin.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Linagliptin.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be decreased when combined with Linagliptin.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Linagliptin.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Linagliptin.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Linagliptin can be increased when used in combination with Clopamide.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Linagliptin.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Linagliptin.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Linagliptin.]
[A04AA02, granisetron, The metabolism of Granisetron can be decreased when combined with Linagliptin.]
[N05AH02, clozapine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Linagliptin.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Guar gum.]
[A10BK06, sotagliflozin, The serum concentration of Linagliptin can be increased when it is combined with Sotagliflozin.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Linagliptin.]
[H01AC08, somatrogon, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Somatrogon.]
[M09AX11, palovarotene, The metabolism of Palovarotene can be decreased when combined with Linagliptin.]
[L04AC21, bimekizumab, The metabolism of Linagliptin can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Linagliptin.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Linagliptin.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Linagliptin.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Linagliptin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Linagliptin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Linagliptin.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Linagliptin.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Linagliptin.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Linagliptin.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Linagliptin.]
[J02AC02, itraconazole, The metabolism of Linagliptin can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Linagliptin is combined with Acyclovir.]
[N05BA10, ketazolam, The metabolism of Ketazolam can be decreased when combined with Linagliptin.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Linagliptin.]
[J02AC04, posaconazole, The metabolism of Linagliptin can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Linagliptin.]
[C08CA09, lacidipine, The metabolism of Lacidipine can be decreased when combined with Linagliptin.]
[N03AX09, lamotrigine, The serum concentration of Linagliptin can be increased when it is combined with Lamotrigine.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Linagliptin.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Lomefloxacin.]
[R06AX13, loratadine, The metabolism of Loratadine can be decreased when combined with Linagliptin.]
[C09AA03, lisinopril, The risk or severity of angioedema can be increased when Linagliptin is combined with Lisinopril.]
[C08CA11, manidipine, The metabolism of Manidipine can be decreased when combined with Linagliptin.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Linagliptin.]
[C07AA14, mepindolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Linagliptin.]
[R06AD07, mequitazine, The metabolism of Linagliptin can be decreased when combined with Mequitazine.]
[C04AX01, cyclandelate, The metabolism of Cyclandelate can be decreased when combined with Linagliptin.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Linagliptin.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Cyclopenthiazide.]
[J01FA03, midecamycin, The metabolism of Midecamycin can be decreased when combined with Linagliptin.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Miglitol is combined with Linagliptin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Linagliptin.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Linagliptin.]
[N06AX07, minaprine, Minaprine may increase the hypoglycemic activities of Linagliptin.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.]
[N06AG02, moclobemide, Moclobemide may increase the hypoglycemic activities of Linagliptin.]
[N06BA07, modafinil, The metabolism of Linagliptin can be increased when combined with Modafinil.]
[C09AA13, moexipril, The risk or severity of angioedema can be increased when Linagliptin is combined with Moexipril.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Linagliptin.]
[C03XA02, conivaptan, The metabolism of Linagliptin can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Linagliptin is combined with Cytarabine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Linagliptin.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Linagliptin.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Linagliptin.]
[G03XA01, danazol, The metabolism of Linagliptin can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Linagliptin.]
[L01DB02, daunorubicin, The metabolism of Linagliptin can be decreased when combined with Daunorubicin.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Linagliptin.]
[C07AB12, nebivolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Linagliptin can be decreased when combined with Nefazodone.]
[N03AG06, tiagabine, The metabolism of Tiagabine can be decreased when combined with Linagliptin.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be decreased when combined with Linagliptin.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Linagliptin.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Linagliptin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Linagliptin.]
[N06AA01, desipramine, Desipramine may decrease the hypoglycemic activities of Linagliptin.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Linagliptin.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Linagliptin.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Linagliptin.]
[C09XA02, aliskiren, The metabolism of Aliskiren can be decreased when combined with Linagliptin.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Linagliptin.]
[N03AF02, oxcarbazepine, The metabolism of Linagliptin can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Linagliptin.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be decreased when combined with Linagliptin.]
[L04AB04, adalimumab, The metabolism of Linagliptin can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Linagliptin.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Linagliptin.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Linagliptin.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Linagliptin.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Linagliptin.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Linagliptin.]
[V03AH01, diazoxide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Diazoxide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Linagliptin.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Linagliptin can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Linagliptin.]
[J01CF01, dicloxacillin, The metabolism of Linagliptin can be increased when combined with Dicloxacillin.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Linagliptin can be increased when used in combination with Phthalylsulfathiazole.]
[C02DG01, pinacidil, The metabolism of Pinacidil can be decreased when combined with Linagliptin.]
[A03AX04, pinaverium, The metabolism of Pinaverium can be decreased when combined with Linagliptin.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Linagliptin.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Linagliptin.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Linagliptin.]
[C03CA03, piretanide, The therapeutic efficacy of Linagliptin can be increased when used in combination with Piretanide.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Linagliptin.]
[C08CA03, isradipine, The metabolism of Linagliptin can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Linagliptin.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Linagliptin.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Linagliptin.]
[C01AA05, digoxin, Linagliptin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Linagliptin.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Linagliptin.]
[J05AE08, atazanavir, The metabolism of Linagliptin can be decreased when combined with Atazanavir.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Linagliptin.]
[C08DB01, diltiazem, The metabolism of Linagliptin can be decreased when combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The metabolism of Linagliptin can be decreased when combined with Dimethyl sulfoxide.]
[G02AD02, dinoprostone, The serum concentration of Linagliptin can be increased when it is combined with Dinoprostone.]
[C05CA03, diosmin, The serum concentration of Linagliptin can be increased when it is combined with Diosmin.]
[R06AA02, diphenhydramine, The serum concentration of Linagliptin can be increased when it is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Linagliptin.]
[C09AA06, quinapril, The risk or severity of angioedema can be increased when Linagliptin is combined with Quinapril.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Linagliptin.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Linagliptin.]
[C09AA05, ramipril, The risk or severity of angioedema can be increased when Linagliptin is combined with Ramipril.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Linagliptin.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Linagliptin.]
[P03AA04, disulfiram, The metabolism of Disulfiram can be decreased when combined with Linagliptin.]
[S02AA12, rifamycin SV, The metabolism of Linagliptin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Linagliptin can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Linagliptin.]
[N05AX08, risperidone, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, The metabolism of Levocetirizine can be decreased when combined with Linagliptin.]
[J01MB01, rosoxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Linagliptin.]
[A04AD12, aprepitant, The metabolism of Linagliptin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Linagliptin.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Linagliptin.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be decreased when combined with Linagliptin.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Linagliptin.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Linagliptin.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be decreased when combined with Linagliptin.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Linagliptin.]
[C01CA04, dopamine, The serum concentration of Linagliptin can be increased when it is combined with Dopamine.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Linagliptin.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Linagliptin.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Linagliptin.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Linagliptin.]
[A08AA10, sibutramine, The metabolism of Sibutramine can be decreased when combined with Linagliptin.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Linagliptin.]
[C09AA11, spirapril, The risk or severity of angioedema can be increased when Linagliptin is combined with Spirapril.]
[G03DB01, dydrogesterone, The metabolism of Dydrogesterone can be decreased when combined with Linagliptin.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Linagliptin can be increased when used in combination with Succinylsulfathiazole.]
[N02CC01, sumatriptan, The therapeutic efficacy of Linagliptin can be increased when used in combination with Sumatriptan.]
[C07AB13, talinolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Linagliptin.]
[J01MA05, temafloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Linagliptin.]
[G04BD05, terodiline, The metabolism of Terodiline can be decreased when combined with Linagliptin.]
[C07AA16, tertatolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Linagliptin.]
[C09AA02, enalapril, The risk or severity of angioedema can be increased when Linagliptin is combined with Enalapril.]
[M01AG02, tolfenamic acid, The metabolism of Tolfenamic acid can be decreased when combined with Linagliptin.]
[N06AG03, toloxatone, Toloxatone may increase the hypoglycemic activities of Linagliptin.]
[N03AX11, topiramate, The metabolism of Linagliptin can be increased when combined with Topiramate.]
[L02BA02, toremifene, The metabolism of Toremifene can be decreased when combined with Linagliptin.]
[C03CA04, torsemide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide.]
[C09AA10, trandolapril, The risk or severity of angioedema can be increased when Linagliptin is combined with Trandolapril.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Linagliptin.]
[L02AE04, triptorelin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Triptorelin.]
[J01MA04, enoxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Linagliptin.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Linagliptin.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Linagliptin.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Linagliptin.]
[C08CA12, mepirodipine, The metabolism of Barnidipine can be decreased when combined with Linagliptin.]
[S01EA01, epinephrine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Epinephrine.]
[C09AA15, zofenopril, The risk or severity of angioedema can be increased when Linagliptin is combined with Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Linagliptin.]
[M01AB04, zomepirac, The metabolism of Zomepirac can be decreased when combined with Linagliptin.]
[N03AX15, zonisamide, The metabolism of Zonisamide can be decreased when combined with Linagliptin.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Linagliptin.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Linagliptin.]
[B01AD03, anistreplase, The risk or severity of angioedema can be increased when Anistreplase is combined with Linagliptin.]
[C02AC02, guanfacine, The metabolism of Guanfacine can be decreased when combined with Linagliptin.]
[G02AB03, ergonovine, The metabolism of Ergometrine can be decreased when combined with Linagliptin.]
[C04AE01, ergoloid mesylates, USP, The metabolism of Ergoloid mesylate can be decreased when combined with Linagliptin.]
[N02CA02, ergotamine, The metabolism of Linagliptin can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Linagliptin can be decreased when combined with Valproic acid.]
[S01AA17, erythromycin, The metabolism of Linagliptin can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The metabolism of Estazolam can be decreased when combined with Linagliptin.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Linagliptin.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Linagliptin.]
[G03CA03, estradiol, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Estradiol.]
[L01XX11, estramustine, The metabolism of Estramustine can be decreased when combined with Linagliptin.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Linagliptin.]
[J04AK02, ethambutol, The metabolism of Linagliptin can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Linagliptin.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Linagliptin.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Linagliptin.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Linagliptin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ethinylestradiol.]
[N03AD01, ethosuximide, The metabolism of Ethosuximide can be decreased when combined with Linagliptin.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be decreased when combined with Linagliptin.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Linagliptin.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Linagliptin.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Linagliptin.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Linagliptin.]
[J01MA08, fleroxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Linagliptin.]
[R06AX12, terfenadine, The metabolism of Linagliptin can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The excretion of Linagliptin can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Linagliptin.]
[L02AE02, leuprolide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Linagliptin.]
[A05AA01, chenodeoxycholic acid, The metabolism of Chenodeoxycholic acid can be decreased when combined with Linagliptin.]
[A02BA03, famotidine, The serum concentration of Linagliptin can be increased when it is combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Linagliptin.]
[C08CA02, felodipine, The metabolism of Felodipine can be decreased when combined with Linagliptin.]
[C08EA01, fendiline, The metabolism of Fendiline can be decreased when combined with Linagliptin.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Linagliptin.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Linagliptin.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Linagliptin.]
[J01CF05, floxacillin, The metabolism of Linagliptin can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Linagliptin.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Linagliptin.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Linagliptin.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Linagliptin.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Linagliptin.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Linagliptin.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Linagliptin.]
[V03AZ01, ethanol, The metabolism of Ethanol can be decreased when combined with Linagliptin.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Linagliptin.]
[N06AB03, fluoxetine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Linagliptin.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Linagliptin.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Linagliptin.]
[N05CD01, flurazepam, The metabolism of Flurazepam can be decreased when combined with Linagliptin.]
[N05AG01, fluspirilene, The metabolism of Fluspirilene can be decreased when combined with Linagliptin.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Linagliptin.]
[G01AX06, furazolidone, Furazolidone may increase the hypoglycemic activities of Linagliptin.]
[J05AE10, darunavir, The metabolism of Linagliptin can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Linagliptin.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Linagliptin.]
[C08DA02, gallopamil, The metabolism of Gallopamil can be decreased when combined with Linagliptin.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Linagliptin is combined with Ganciclovir.]
[N03AA04, barbexaclone, The metabolism of Linagliptin can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Gemfibrozil can be decreased when combined with Linagliptin.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Linagliptin.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Linagliptin.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Linagliptin.]
[J05AG04, etravirine, The metabolism of Linagliptin can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Linagliptin.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be decreased when combined with Linagliptin.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be decreased when combined with Linagliptin.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Linagliptin.]
[A10BB01, glyburide, Linagliptin may increase the hypoglycemic activities of Glyburide.]
[A10BB09, gliclazide, Linagliptin may increase the hypoglycemic activities of Gliclazide.]
[A10BB07, glipizide, Linagliptin may increase the hypoglycemic activities of Glipizide.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Linagliptin.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Linagliptin.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Linagliptin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Linagliptin.]
[C09AA09, fosinopril, The risk or severity of angioedema can be increased when Linagliptin is combined with Fosinopril.]
[D01BA01, griseofulvin, The metabolism of Linagliptin can be increased when combined with Griseofulvin.]
[L02AE03, goserelin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Linagliptin.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Linagliptin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Linagliptin.]
[L02AE05, histrelin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Quetiapine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin aspart.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Linagliptin.]
[C09CA01, losartan, The metabolism of Losartan can be decreased when combined with Linagliptin.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Linagliptin.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Linagliptin.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Linagliptin.]
[C08CA10, nilvadipine, The metabolism of Linagliptin can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The metabolism of Nimesulide can be decreased when combined with Linagliptin.]
[C09AA04, perindopril, The risk or severity of angioedema can be increased when Linagliptin is combined with Perindopril.]
[C02DB02, hydralazine, The metabolism of Linagliptin can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Linagliptin.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Linagliptin.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Linagliptin.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Linagliptin.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroflumethiazide.]
[G04BD06, propiverine, The metabolism of Propiverine can be decreased when combined with Linagliptin.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Hydroxychloroquine.]
[G03DA03, 17-alpha-hydroxyprogesterone, The metabolism of Hydroxyprogesterone can be decreased when combined with Linagliptin.]
[N05BB01, hydroxyzine, The metabolism of Hydroxyzine can be decreased when combined with Linagliptin.]
[J04AB04, rifabutin, The metabolism of Rifabutin can be decreased when combined with Linagliptin.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Linagliptin.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Linagliptin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Linagliptin.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Linagliptin.]
[N01AH03, sufentanil, The metabolism of Sufentanil can be decreased when combined with Linagliptin.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Linagliptin.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Linagliptin.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Linagliptin.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Linagliptin.]
[C03BA11, indapamide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Linagliptin.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Linagliptin.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Linagliptin.]
[N01BB08, articaine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Linagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Linagliptin.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Linagliptin.]
[A10BH02, vildagliptin, The risk or severity of angioedema can be increased when Vildagliptin is combined with Linagliptin.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Linagliptin.]
[C07AA01, alprenolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Quinethazone.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Linagliptin.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Linagliptin.]
[N06AF05, iproniazid, Iproniazid may increase the hypoglycemic activities of Linagliptin.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypoglycemic activities of Linagliptin.]
[P01AX06, atovaquone, The metabolism of Atovaquone can be decreased when combined with Linagliptin.]
[C09AA16, imidapril, The risk or severity of angioedema can be increased when Linagliptin is combined with Imidapril.]
[J04AC01, isoniazid, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Isoniazid.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Exenatide is combined with Linagliptin.]
[D10BA01, isotretinoin, The metabolism of Isotretinoin can be decreased when combined with Linagliptin.]
[P02CF01, ivermectin, The metabolism of Ivermectin can be decreased when combined with Linagliptin.]
[N06AX18, reboxetine, The metabolism of Reboxetine can be decreased when combined with Linagliptin.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Linagliptin.]
[L04AC07, tocilizumab, The metabolism of Linagliptin can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Linagliptin.]
[J02AB02, ketoconazole, The metabolism of Linagliptin can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Linagliptin can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine.]
[V03AC03, deferasirox, The metabolism of Linagliptin can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Linagliptin can be increased when combined with Abatacept.]
[S01GX08, ketotifen, The risk or severity of thrombocytopenia can be increased when Linagliptin is combined with Ketotifen.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be decreased when combined with Linagliptin.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Linagliptin.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Linagliptin can be increased when used in combination with Nalidixic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Labetalol.]
[N04BB01, amantadine, The serum concentration of Linagliptin can be increased when it is combined with Amantadine.]
[J05AX09, maraviroc, The metabolism of Maraviroc can be decreased when combined with Linagliptin.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Linagliptin.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.]
[R05CB06, ambroxol, The metabolism of Ambroxol can be decreased when combined with Linagliptin.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Levonorgestrel.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Linagliptin.]
[C08EX01, lidoflazine, The metabolism of Lidoflazine can be decreased when combined with Linagliptin.]
[N06BA13, armodafinil, The metabolism of Linagliptin can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Linagliptin.]
[C03DB01, amiloride, The serum concentration of Linagliptin can be increased when it is combined with Amiloride.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Linagliptin.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Linagliptin.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Linagliptin.]
[N05BA06, lorazepam, The metabolism of Lorazepam can be decreased when combined with Linagliptin.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Linagliptin.]
[N05AH01, loxapine, The serum concentration of Linagliptin can be increased when it is combined with Loxapine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Linagliptin.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Linagliptin.]
[V04CC02, magnesium sulfate, The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Linagliptin.]
[L01EA03, nilotinib, The metabolism of Linagliptin can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Linagliptin.]
[C01AA08, medigoxin, Linagliptin may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[G03DB03, medrogestone, The metabolism of Medrogestone can be decreased when combined with Linagliptin.]
[P01BC02, mefloquine, The metabolism of Mefloquine can be decreased when combined with Linagliptin.]
[C03BA05, mefruside, The therapeutic efficacy of Linagliptin can be increased when used in combination with Mefruside.]
[N06DX01, memantine, The serum concentration of Memantine can be increased when it is combined with Linagliptin.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Linagliptin.]
[N03AA01, mephobarbital, The metabolism of Linagliptin can be increased when combined with Methylphenobarbital.]
[L02BG01, aminoglutethimide, The metabolism of Linagliptin can be increased when combined with Aminoglutethimide.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Linagliptin.]
[N05AX13, paliperidone, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Paliperidone.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Linagliptin.]
[H01CB03, lanreotide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lanreotide.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Linagliptin.]
[N05CM01, methaqualone, The metabolism of Methaqualone can be decreased when combined with Linagliptin.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Linagliptin.]
[S01EC05, methazolamide, The therapeutic efficacy of Linagliptin can be increased when used in combination with Methazolamide.]
[H03BB02, methimazole, The metabolism of Linagliptin can be decreased when combined with Methimazole.]
[N02BG08, ziconotide, The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Linagliptin.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Linagliptin.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methotrimeprazine.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methyclothiazide.]
[V04CG05, methylene blue, The serum concentration of Methylene blue can be increased when it is combined with Linagliptin.]
[G02AB01, methylergonovine, The metabolism of Methylergometrine can be decreased when combined with Linagliptin.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Linagliptin.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Linagliptin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Linagliptin.]
[N03AF03, rufinamide, The metabolism of Linagliptin can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Linagliptin.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Linagliptin.]
[A03FA01, metoclopramide, The metabolism of Metoclopramide can be decreased when combined with Linagliptin.]
[C03BA08, metolazone, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Linagliptin can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Linagliptin can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Linagliptin.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Linagliptin.]
[S02AA13, miconazole, The metabolism of Linagliptin can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Linagliptin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Linagliptin.]
[G03XB01, mifepristone, The serum concentration of Linagliptin can be decreased when it is combined with Mifepristone.]
[C09CA03, valsartan, The risk or severity of angioedema can be increased when Valsartan is combined with Linagliptin.]
[J01FA11, miocamycin, The metabolism of Linagliptin can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Linagliptin can be increased when combined with Mitotane.]
[L03AC01, aldesleukin, The metabolism of Linagliptin can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Linagliptin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the hypoglycemic activities of Linagliptin.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Linagliptin.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Linagliptin.]
[L04AB05, certolizumab pegol, The metabolism of Linagliptin can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Linagliptin.]
[N05CA02, amobarbital, The metabolism of Linagliptin can be increased when combined with Amobarbital.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Linagliptin.]
[G03XC01, raloxifene, The metabolism of Linagliptin can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Linagliptin.]
[N03AB05, fosphenytoin, The metabolism of Linagliptin can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Nadolol.]
[J01CF06, nafcillin, The metabolism of Linagliptin can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Linagliptin can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Linagliptin can be increased when combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Linagliptin.]
[A10BG01, troglitazone, The metabolism of Linagliptin can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Linagliptin.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Linagliptin.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Linagliptin.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Linagliptin.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Linagliptin.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Linagliptin.]
[C09CA07, telmisartan, The risk or severity of angioedema can be increased when Telmisartan is combined with Linagliptin.]
[H05BX02, paricalcitol, The metabolism of Paricalcitol can be decreased when combined with Linagliptin.]
[C10AD02, niacin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypoglycemic activities of Linagliptin.]
[C08CA04, nicardipine, The metabolism of Linagliptin can be decreased when combined with Nicardipine.]
[N07BA01, nicotine, The serum concentration of Linagliptin can be increased when it is combined with Nicotine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Linagliptin.]
[C08CA06, nimodipine, The metabolism of Nimodipine can be decreased when combined with Linagliptin.]
[C08CA07, nisoldipine, The metabolism of Nisoldipine can be decreased when combined with Linagliptin.]
[N05CD02, nitrazepam, The metabolism of Nitrazepam can be decreased when combined with Linagliptin.]
[C08CA08, nitrendipine, The metabolism of Nitrendipine can be decreased when combined with Linagliptin.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be decreased when combined with Linagliptin.]
[N04BC05, pramipexole, The serum concentration of Pramipexole can be increased when it is combined with Linagliptin.]
[C01CA03, norepinephrine, The serum concentration of Linagliptin can be increased when it is combined with Norepinephrine.]
[G03DC02, norethindrone, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Linagliptin can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Linagliptin.]
[R05DA07, noscapine, The metabolism of Linagliptin can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Linagliptin can be increased when it is combined with Sapropterin.]
[G02CA02, nylidrin, The metabolism of Nylidrin can be decreased when combined with Linagliptin.]
[H01CB02, octreotide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Ofloxacin.]
[J01FA05, oleandomycin, The metabolism of Linagliptin can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Linagliptin can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Linagliptin.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Linagliptin.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Linagliptin.]
[B01AD07, reteplase, The risk or severity of angioedema can be increased when Reteplase is combined with Linagliptin.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Linagliptin.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Linagliptin.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Linagliptin can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Linagliptin.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Linagliptin.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Linagliptin.]
[V04CH30, 4-aminohippuric acid, The serum concentration of Linagliptin can be increased when it is combined with Aminohippuric acid.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Linagliptin.]
[N05AH05, asenapine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Asenapine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Linagliptin is combined with Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be decreased when combined with Linagliptin.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Linagliptin.]
[C02KC01, pargyline, Pargyline may increase the hypoglycemic activities of Linagliptin.]
[J01MA03, pefloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Linagliptin.]
[C07AA23, penbutolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The metabolism of Penfluridol can be decreased when combined with Linagliptin.]
[N05CA01, pentobarbital, The metabolism of Linagliptin can be increased when combined with Pentobarbital.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Linagliptin.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Linagliptin.]
[N06AF03, phenelzine, Phenelzine may increase the hypoglycemic activities of Linagliptin.]
[A10BA01, phenformin, The serum concentration of Linagliptin can be increased when it is combined with Phenformin.]
[N03AA02, phenobarbital, The metabolism of Linagliptin can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, The serum concentration of Linagliptin can be increased when it is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Linagliptin.]
[A08AA01, phentermine, The therapeutic efficacy of Linagliptin can be increased when used in combination with Phentermine.]
[M02AA01, phenylbutazone, The metabolism of Linagliptin can be increased when combined with Phenylbutazone.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Linagliptin.]
[N03AB02, phenytoin, The metabolism of Linagliptin can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Linagliptin can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Linagliptin.]
[C08CX01, mibefradil, The metabolism of Mibefradil can be decreased when combined with Linagliptin.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Linagliptin.]
[C07AA03, pindolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Linagliptin.]
[J05AE01, saquinavir, The metabolism of Linagliptin can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pipotiazine.]
[C09CA02, eprosartan, The risk or severity of angioedema can be increased when Eprosartan is combined with Linagliptin.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Linagliptin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Linagliptin can be decreased when combined with Irbesartan.]
[S01XA13, alteplase, The risk or severity of angioedema can be increased when Alteplase is combined with Linagliptin.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Linagliptin.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Linagliptin.]
[L04AC08, canakinumab, The metabolism of Linagliptin can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Linagliptin can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Linagliptin.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin lispro.]
[C07AB01, practolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Practolol.]
[N05BA11, prazepam, The metabolism of Prazepam can be decreased when combined with Linagliptin.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Linagliptin.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Linagliptin.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Linagliptin.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Linagliptin.]
[C01DX02, prenylamine, The metabolism of Prenylamine can be decreased when combined with Linagliptin.]
[P01BA03, primaquine, The metabolism of Linagliptin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Linagliptin can be increased when combined with Primidone.]
[M04AB01, probenecid, The therapeutic efficacy of Linagliptin can be increased when used in combination with Probenecid.]
[C01BA02, procainamide, The serum concentration of Procainamide can be increased when it is combined with Linagliptin.]
[S01HA05, procaine, Procaine may increase the hypoglycemic activities of Linagliptin.]
[L01XB01, procarbazine, Procarbazine may increase the hypoglycemic activities of Linagliptin.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Linagliptin.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Linagliptin.]
[G03DA04, progesterone, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Progesterone.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Linagliptin.]
[G03DB07, promegestone, The metabolism of Promegestone can be decreased when combined with Linagliptin.]
[C01BC03, propafenone, The therapeutic efficacy of Linagliptin can be increased when used in combination with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Linagliptin.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Linagliptin.]
[N01AX10, propofol, The metabolism of Linagliptin can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Linagliptin.]
[C07AA05, propranolol, The therapeutic efficacy of Linagliptin can be increased when used in combination with Propranolol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Linagliptin.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Linagliptin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Linagliptin.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Linagliptin.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Linagliptin.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Linagliptin.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Quinine is combined with Linagliptin.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Linagliptin.]
[A02BA02, ranitidine, The serum concentration of Linagliptin can be increased when it is combined with Ranitidine.]
[C02AA01, rescinnamine, The risk or severity of angioedema can be increased when Linagliptin is combined with Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Linagliptin can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The serum concentration of Linagliptin can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Roxithromycin can be decreased when combined with Linagliptin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Linagliptin.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Linagliptin.]
[S01FA02, scopolamine, The metabolism of Scopolamine can be decreased when combined with Linagliptin.]
[N05CA06, secobarbital, The metabolism of Linagliptin can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Linagliptin.]
[H01CB01, somatostatin, The metabolism of Linagliptin can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Linagliptin.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Linagliptin.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Linagliptin.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Empagliflozin.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Empagliflozin.]
[J01EC02, sulfadiazine, Empagliflozin may increase the hypoglycemic activities of Sulfadiazine.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, Empagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfapyridine.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, Empagliflozin may increase the hypoglycemic activities of Sulfisoxazole.]
[A10BB04, glibornuride, Empagliflozin may increase the hypoglycemic activities of Glibornuride.]
[A10BC01, glymidine, Empagliflozin may increase the hypoglycemic activities of Glymidine.]
[G03BA03, testosterone, Testosterone may increase the hypoglycemic activities of Empagliflozin.]
[N05AE05, lurasidone, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Empagliflozin.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Empagliflozin.]
[R03DA07, theobromine, Empagliflozin may increase the diuretic activities of Theobromine.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Empagliflozin.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Empagliflozin.]
[S01ED01, timolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Timolol.]
[A10BB05, tolazamide, Empagliflozin may increase the hypoglycemic activities of Tolazamide.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Empagliflozin.]
[V04CA01, tolbutamide, Empagliflozin may increase the hypoglycemic activities of Tolbutamide.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Empagliflozin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Empagliflozin.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Empagliflozin.]
[C03DB02, triamterene, Empagliflozin may increase the diuretic activities of Triamterene.]
[C03AA06, trichlormethiazide, Empagliflozin may increase the diuretic activities of Trichlormethiazide.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Empagliflozin.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Empagliflozin.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Empagliflozin.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Empagliflozin.]
[A03AA05, trimebutine, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Empagliflozin.]
[N03AC02, trimethadione, The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Empagliflozin.]
[C02BA01, trimethaphan, Empagliflozin may increase the hypotensive activities of Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may decrease the hypoglycemic activities of Empagliflozin.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.]
[C08DA01, verapamil, The risk or severity of hypoglycemia can be increased when Verapamil is combined with Empagliflozin.]
[C04AX07, vincamine, Empagliflozin may increase the hypotensive activities of Vincamine.]
[C03BA10, xipamide, Empagliflozin may increase the diuretic activities of Xipamide.]
[J05AE02, indinavir, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indinavir.]
[L01EC01, vemurafenib, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Vemurafenib.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, Empagliflozin may increase the diuretic activities of Drospirenone.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Empagliflozin.]
[C07AB03, atenolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Atenolol.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Empagliflozin.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Empagliflozin.]
[M03BX01, baclofen, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Baclofen.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Empagliflozin.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Empagliflozin.]
[J05AE04, nelfinavir, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Empagliflozin.]
[C08CA13, lercanidipine, The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Empagliflozin.]
[H01CB05, pasireotide, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of hypotension can be increased when Sildenafil is combined with Empagliflozin.]
[C04AX11, bencyclane, The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Empagliflozin.]
[A10BH04, alogliptin, Empagliflozin may increase the hypoglycemic activities of Alogliptin.]
[C03AA01, bendroflumethiazide, Empagliflozin may increase the diuretic activities of Bendroflumethiazide.]
[A10BK02, canagliflozin, Empagliflozin may increase the diuretic activities of Canagliflozin.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gemifloxacin.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Moxifloxacin.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Empagliflozin.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin detemir.]
[A10BX05, pramlintide, Empagliflozin may increase the hypoglycemic activities of Pramlintide.]
[M01AH01, celecoxib, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Celecoxib.]
[L04AA18, everolimus, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.]
[L01EC02, dabrafenib, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Empagliflozin.]
[C08EA02, bepridil, The risk or severity of hypoglycemia can be increased when Bepridil is combined with Empagliflozin.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Riociguat is combined with Empagliflozin.]
[A10BJ03, lixisenatide, Empagliflozin may increase the hypoglycemic activities of Lixisenatide.]
[C02KX04, macitentan, Empagliflozin may increase the hypotensive activities of Macitentan.]
[G03AC08, etonogestrel, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Simeprevir.]
[A10BK01, dapagliflozin, Empagliflozin may increase the diuretic activities of Dapagliflozin.]
[C07AB04, acebutolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Acebutolol.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Empagliflozin.]
[S01ED02, betaxolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Betaxolol.]
[C02CC01, bethanidine, Empagliflozin may increase the hypotensive activities of Bethanidine.]
[A10BJ04, albiglutide, Empagliflozin may increase the hypoglycemic activities of Albiglutide.]
[L01ED02, ceritinib, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Pipemidic acid.]
[A10BJ05, dulaglutide, Empagliflozin may increase the hypoglycemic activities of Dulaglutide.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.]
[A10BF01, acarbose, Empagliflozin may increase the hypoglycemic activities of Acarbose.]
[S01EC01, acetazolamide, Empagliflozin may increase the diuretic activities of Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin degludec.]
[B01AC27, selexipag, Empagliflozin may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, Empagliflozin may increase the hypoglycemic activities of Acetohexamide.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Empagliflozin.]
[N04BC01, bromocriptine, Empagliflozin may increase the hypoglycemic activities of Bromocriptine.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Empagliflozin.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Empagliflozin.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Empagliflozin.]
[C03CA02, bumetanide, Empagliflozin may increase the diuretic activities of Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Empagliflozin.]
[C07AA19, bupranolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bupranolol.]
[L02AE01, buserelin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Buserelin.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Arsenic trioxide.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sparfloxacin.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Empagliflozin.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Empagliflozin.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Empagliflozin.]
[A10BX06, benfluorex, Empagliflozin may increase the hypoglycemic activities of Benfluorex.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Empagliflozin.]
[J05AE09, tipranavir, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Empagliflozin.]
[J01MA23, delafloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Delafloxacin.]
[L01XH01, vorinostat, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bisoprolol.]
[S01EC04, brinzolamide, Empagliflozin may increase the diuretic activities of Brinzolamide.]
[C07AA17, bopindolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Nesiritide is combined with Empagliflozin.]
[C03DA03, canrenone, Empagliflozin may increase the diuretic activities of Canrenone.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Empagliflozin.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Empagliflozin.]
[A10BJ06, semaglutide, Empagliflozin may increase the hypoglycemic activities of Semaglutide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ertugliflozin.]
[C09AA01, captopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Captopril.]
[C07AG02, carvedilol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Empagliflozin.]
[C07AB08, celiprolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Celiprolol.]
[A10BB06, carbutamide, Empagliflozin may increase the hypoglycemic activities of Carbutamide.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Empagliflozin.]
[C09AA08, cilazapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Cilazapril.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Empagliflozin.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Empagliflozin.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Empagliflozin.]
[C09CA06, candesartan, Empagliflozin may increase the hypotensive activities of Candesartan.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Empagliflozin.]
[C03BX03, cicletanine, Empagliflozin may increase the diuretic activities of Cicletanine.]
[C03AA09, cyclothiazide, Empagliflozin may increase the diuretic activities of Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin pork.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Empagliflozin.]
[G03AC09, desogestrel, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Desogestrel.]
[L04AA53, teprotumumab, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Teprotumumab.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gatifloxacin.]
[G03DB08, dienogest, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Empagliflozin.]
[C08CA16, clevidipine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Empagliflozin.]
[C02AA06, methoserpidine, Empagliflozin may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Empagliflozin is combined with Opicapone.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Empagliflozin.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Empagliflozin.]
[C08CA17, levamlodipine, The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Empagliflozin.]
[C03AA04, chlorothiazide, Empagliflozin may increase the diuretic activities of Chlorothiazide.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, Empagliflozin may increase the hypoglycemic activities of Chlorpropamide.]
[C03BA04, chlorthalidone, Empagliflozin may increase the diuretic activities of Chlorthalidone.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Empagliflozin.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Empagliflozin.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Empagliflozin is combined with Vericiguat.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Fenoldopam is combined with Empagliflozin.]
[J01MB07, flumequine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Empagliflozin.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Empagliflozin.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin human.]
[H04AA02, dasiglucagon, Empagliflozin may increase the hypotensive activities of Dasiglucagon.]
[N07CA02, cinnarizine, The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Empagliflozin.]
[J01MB06, cinoxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Cinoxacin.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Empagliflozin.]
[H01AC07, somapacitan, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, Empagliflozin may increase the diuretic activities of Finerenone.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lonapegsomatropin.]
[A10BB12, glimepiride, Empagliflozin may increase the hypoglycemic activities of Glimepiride.]
[A10BB08, gliquidone, Empagliflozin may increase the hypoglycemic activities of Gliquidone.]
[N06AX25, St. John's wort extract, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with St. John's Wort.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Empagliflozin.]
[B06AX04, mitapivat, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Empagliflozin.]
[N06AA04, clomipramine, Clomipramine may decrease the hypoglycemic activities of Empagliflozin.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.]
[A10BX16, tirzepatide, Empagliflozin may increase the hypoglycemic activities of Tirzepatide.]
[C03BA03, clopamide, Empagliflozin may increase the diuretic activities of Clopamide.]
[N05AH02, clozapine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Clozapine.]
[A10BX01, guar gum, Empagliflozin may increase the hypoglycemic activities of Guar gum.]
[A10BK06, sotagliflozin, Empagliflozin may increase the hypoglycemic activities of Sotagliflozin.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Empagliflozin.]
[H01AC08, somatrogon, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somatrogon.]
[C02KB01, metyrosine, Empagliflozin may increase the hypotensive activities of Metyrosine.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Empagliflozin.]
[A10BX03, nateglinide, Empagliflozin may increase the hypoglycemic activities of Nateglinide.]
[H01AC03, mecasermin, Empagliflozin may increase the hypoglycemic activities of Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glargine.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Empagliflozin.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.]
[C08CA09, lacidipine, Empagliflozin may increase the hypotensive activities of Lacidipine.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Empagliflozin.]
[N07BC04, lofexidine, The risk or severity of adverse effects can be increased when Lofexidine is combined with Empagliflozin.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Lomefloxacin.]
[C09AA03, lisinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Lisinopril.]
[C08CA11, manidipine, The risk or severity of hypoglycemia can be increased when Manidipine is combined with Empagliflozin.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Empagliflozin.]
[C07AA14, mepindolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Empagliflozin.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Empagliflozin.]
[C03DA04, eplerenone, Empagliflozin may increase the diuretic activities of Eplerenone.]
[C03AA07, cyclopenthiazide, Empagliflozin may increase the diuretic activities of Cyclopenthiazide.]
[A10BF02, miglitol, Empagliflozin may increase the hypoglycemic activities of Miglitol.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Empagliflozin.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Empagliflozin.]
[C09AA13, moexipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Moexipril.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Rosuvastatin.]
[C03XA02, conivaptan, Empagliflozin may increase the diuretic activities of Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Empagliflozin is combined with Moxonidine.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Empagliflozin.]
[G03XA01, danazol, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Danazol.]
[C02CC04, debrisoquin, Empagliflozin may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Empagliflozin.]
[C07AB12, nebivolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nebivolol.]
[N06AX06, nefazodone, The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Empagliflozin.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Empagliflozin.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Empagliflozin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Empagliflozin.]
[N06AA01, desipramine, Desipramine may decrease the hypoglycemic activities of Empagliflozin.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Empagliflozin.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Empagliflozin.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Empagliflozin.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Empagliflozin.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Empagliflozin.]
[V03AH01, diazoxide, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Diazoxide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Empagliflozin.]
[S01EC02, dichlorphenamide, Empagliflozin may increase the diuretic activities of Diclofenamide.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Phthalylsulfathiazole.]
[C02DG01, pinacidil, Empagliflozin may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Empagliflozin.]
[A10BG03, pioglitazone, Empagliflozin may increase the hypoglycemic activities of Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Empagliflozin is combined with Pipamperone.]
[C03CA03, piretanide, Empagliflozin may increase the diuretic activities of Piretanide.]
[C08CA03, isradipine, The risk or severity of hypoglycemia can be increased when Isradipine is combined with Empagliflozin.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Empagliflozin.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Empagliflozin.]
[C02DB01, dihydralazine, Empagliflozin may increase the hypotensive activities of Dihydralazine.]
[J05AE08, atazanavir, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.]
[B01AC21, treprostinil, Empagliflozin may increase the hypotensive activities of Treprostinil.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Empagliflozin.]
[C08DB01, diltiazem, The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Empagliflozin.]
[C09AA06, quinapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Empagliflozin.]
[C09AA05, ramipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Ramipril.]
[S01XA23, sirolimus, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.]
[C01BA03, disopyramide, Empagliflozin may increase the hypoglycemic activities of Disopyramide.]
[N05AX08, risperidone, Empagliflozin may increase the hypotensive activities of Risperidone.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Empagliflozin.]
[J01MB01, rosoxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, Empagliflozin may increase the hypoglycemic activities of Sunitinib.]
[C03XA01, tolvaptan, Empagliflozin may increase the diuretic activities of Tolvaptan.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, Empagliflozin may increase the hypotensive activities of Tadalafil.]
[C02KX02, ambrisentan, Empagliflozin may increase the hypotensive activities of Ambrisentan.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Empagliflozin.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Empagliflozin.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Empagliflozin.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Empagliflozin.]
[C09AA11, spirapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Spirapril.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Succinylsulfathiazole.]
[N02CC01, sumatriptan, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sumatriptan.]
[C07AB13, talinolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Empagliflozin.]
[J01MA05, temafloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Temafloxacin.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.]
[G04BD05, terodiline, The risk or severity of hypoglycemia can be increased when Terodiline is combined with Empagliflozin.]
[C07AA16, tertatolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Empagliflozin.]
[C09AA02, enalapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Enalapril.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Empagliflozin.]
[C03CA04, torsemide, Empagliflozin may increase the diuretic activities of Torasemide.]
[C09AA10, trandolapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Trandolapril.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Empagliflozin.]
[L02AE04, triptorelin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.]
[C02CA06, urapidil, Empagliflozin may increase the hypotensive activities of Urapidil.]
[J01MA04, enoxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Enoxacin.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Empagliflozin.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Empagliflozin.]
[C08CA12, mepirodipine, The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Empagliflozin.]
[S01EA01, epinephrine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Epinephrine.]
[C09AA15, zofenopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Zofenopril.]
[N03AX15, zonisamide, Empagliflozin may increase the diuretic activities of Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glulisine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Empagliflozin.]
[G03CA03, estradiol, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estradiol.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Empagliflozin.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Empagliflozin.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Empagliflozin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Empagliflozin.]
[N03AD01, ethosuximide, The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Empagliflozin.]
[L04AD02, tacrolimus, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.]
[J01MA08, fleroxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Fleroxacin.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Empagliflozin.]
[L02AE02, leuprolide, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.]
[C08CA02, felodipine, The risk or severity of hypoglycemia can be increased when Felodipine is combined with Empagliflozin.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Empagliflozin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Empagliflozin.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Empagliflozin.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Empagliflozin.]
[N07CA03, flunarizine, The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Empagliflozin.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Empagliflozin.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Empagliflozin.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Empagliflozin.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Empagliflozin.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Empagliflozin.]
[N06AB03, fluoxetine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Empagliflozin.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Empagliflozin.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Empagliflozin.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Empagliflozin.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Empagliflozin.]
[J05AE10, darunavir, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Darunavir.]
[C03CA01, furosemide, Empagliflozin may increase the diuretic activities of Furosemide.]
[C08DA02, gallopamil, The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Empagliflozin.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Empagliflozin.]
[A10BJ02, liraglutide, Empagliflozin may increase the hypoglycemic activities of Liraglutide.]
[N03AD03, methsuximide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Empagliflozin.]
[A10BB01, glyburide, Empagliflozin may increase the hypoglycemic activities of Glyburide.]
[A10BB09, gliclazide, Empagliflozin may increase the hypoglycemic activities of Gliclazide.]
[A10BB07, glipizide, Empagliflozin may increase the hypoglycemic activities of Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Empagliflozin.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.]
[C09AA09, fosinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Fosinopril.]
[S01EX01, guanethidine, Empagliflozin may increase the hypotensive activities of Guanethidine.]
[L02AE03, goserelin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Empagliflozin.]
[N05AD01, haloperidol, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Empagliflozin.]
[L02AE05, histrelin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Histrelin.]
[S01FB03, ibopamine, Empagliflozin may increase the diuretic activities of Ibopamine.]
[N05AH04, quetiapine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quetiapine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin aspart.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Empagliflozin.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Empagliflozin.]
[C08CA10, nilvadipine, The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Empagliflozin.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Empagliflozin.]
[C09AA04, perindopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Perindopril.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.]
[C03AA03, hydrochlorothiazide, Empagliflozin may increase the diuretic activities of Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Empagliflozin.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Empagliflozin.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Empagliflozin.]
[C03AA02, hydroflumethiazide, Empagliflozin may increase the diuretic activities of Hydroflumethiazide.]
[A12BA02, potassium citrate, Empagliflozin may increase the diuretic activities of Potassium citrate.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Hydroxychloroquine.]
[C02AC06, rilmenidine, Empagliflozin may increase the hypotensive activities of Rilmenidine.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Empagliflozin.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Empagliflozin.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Empagliflozin.]
[N06AA02, imipramine, Imipramine may decrease the hypoglycemic activities of Empagliflozin.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Empagliflozin.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Empagliflozin.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.]
[C03BA11, indapamide, Empagliflozin may increase the diuretic activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Empagliflozin.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Indoramin is combined with Empagliflozin.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Empagliflozin.]
[N01BB08, articaine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Articaine.]
[A10BH01, sitagliptin, Empagliflozin may increase the hypoglycemic activities of Sitagliptin.]
[A10BH02, vildagliptin, Empagliflozin may increase the hypoglycemic activities of Vildagliptin.]
[C07AA01, alprenolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, Empagliflozin may increase the diuretic activities of Quinethazone.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Empagliflozin.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Empagliflozin.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Empagliflozin.]
[S01EC03, dorzolamide, Empagliflozin may increase the diuretic activities of Dorzolamide.]
[C09AA16, imidapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Empagliflozin.]
[J04AC01, isoniazid, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Isoniazid.]
[A10BJ01, exenatide, Empagliflozin may increase the hypoglycemic activities of Exenatide.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Empagliflozin.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Empagliflozin.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Empagliflozin.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Empagliflozin.]
[C02KD01, ketanserin, Empagliflozin may increase the hypotensive activities of Ketanserin.]
[N05AH03, olanzapine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Olanzapine.]
[S01GX08, ketotifen, The risk or severity of thrombocytopenia can be increased when Empagliflozin is combined with Ketotifen.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Rotigotine is combined with Empagliflozin.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Empagliflozin.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nalidixic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Labetalol.]
[C02AA05, deserpidine, Empagliflozin may increase the hypotensive activities of Deserpidine.]
[C03CC01, ethacrynic acid, Empagliflozin may increase the diuretic activities of Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Empagliflozin is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Empagliflozin.]
[C03DB01, amiloride, Empagliflozin may increase the diuretic activities of Amiloride.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Empagliflozin.]
[A07DA03, loperamide, The risk or severity of hypoglycemia can be increased when Loperamide is combined with Empagliflozin.]
[L01EG01, temsirolimus, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.]
[V04CC02, magnesium sulfate, The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Empagliflozin.]
[L01EA03, nilotinib, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.]
[V04CX04, mannitol, Empagliflozin may increase the diuretic activities of Mannitol.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.]
[C03BA05, mefruside, Empagliflozin may increase the diuretic activities of Mefruside.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Empagliflozin.]
[C03BC01, mersalyl, Empagliflozin may increase the diuretic activities of Mersalyl.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Empagliflozin.]
[N05AX13, paliperidone, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.]
[H01CB03, lanreotide, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.]
[S01EC05, methazolamide, Empagliflozin may increase the diuretic activities of Methazolamide.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Empagliflozin.]
[N02BG08, ziconotide, The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Empagliflozin.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methotrimeprazine.]
[C03AA08, methyclothiazide, Empagliflozin may increase the diuretic activities of Methyclothiazide.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Empagliflozin.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Empagliflozin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Empagliflozin.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Empagliflozin.]
[C03BA08, metolazone, Empagliflozin may increase the diuretic activities of Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Metoprolol.]
[G03XB01, mifepristone, Empagliflozin may increase the hypoglycemic activities of Mifepristone.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Empagliflozin.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.]
[C01BD01, amiodarone, The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Empagliflozin.]
[N06AA09, amitriptyline, Amitriptyline may decrease the hypoglycemic activities of Empagliflozin.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Empagliflozin.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Empagliflozin.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Empagliflozin.]
[C07AA12, nadolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nadolol.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Empagliflozin.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Empagliflozin.]
[A10BG01, troglitazone, Empagliflozin may increase the hypoglycemic activities of Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Empagliflozin is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Empagliflozin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Empagliflozin.]
[A10BX02, repaglinide, Empagliflozin may increase the hypoglycemic activities of Repaglinide.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Empagliflozin.]
[N05AX14, iloperidone, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Empagliflozin.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Empagliflozin.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.]
[C10AD02, niacin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Empagliflozin.]
[C08CA04, nicardipine, The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Empagliflozin.]
[C08CA05, nifedipine, The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Empagliflozin.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Empagliflozin.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Empagliflozin.]
[C08CA07, nisoldipine, The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Empagliflozin.]
[C08CA08, nitrendipine, The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Empagliflozin.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Empagliflozin.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Empagliflozin.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.]
[G03DC02, norethindrone, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may decrease the hypoglycemic activities of Empagliflozin.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Empagliflozin.]
[H01CB02, octreotide, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ofloxacin.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Empagliflozin.]
[G04CA02, tamsulosin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Tamsulosin.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Empagliflozin.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Oxprenolol.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Empagliflozin.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Empagliflozin.]
[N05AH05, asenapine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Asenapine.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Empagliflozin.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Empagliflozin.]
[J01MA03, pefloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Pefloxacin.]
[C07AA23, penbutolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Empagliflozin.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Empagliflozin.]
[C08EX02, perhexiline, The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Empagliflozin.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Empagliflozin.]
[A10BA01, phenformin, Empagliflozin may increase the hypoglycemic activities of Phenformin.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Empagliflozin.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Empagliflozin.]
[A08AA01, phentermine, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Phentolamine is combined with Empagliflozin.]
[N03AB02, phenytoin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Phenytoin.]
[S01AE05, levofloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Empagliflozin.]
[C07AA03, pindolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Pindolol.]
[J05AE01, saquinavir, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pipotiazine.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Grepafloxacin.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.]
[A10BG02, rosiglitazone, Empagliflozin may increase the hypoglycemic activities of Rosiglitazone.]
[C03AA05, polythiazide, Empagliflozin may increase the diuretic activities of Polythiazide.]
[J05AE03, ritonavir, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.]
[A10BH03, saxagliptin, Empagliflozin may increase the hypoglycemic activities of Saxagliptin.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin lispro.]
[C07AB01, practolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Practolol.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Empagliflozin.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Empagliflozin.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Empagliflozin.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Empagliflozin.]
[M04AB01, probenecid, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Probenecid.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Empagliflozin.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Empagliflozin.]
[G03DA04, progesterone, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.]
[C01BC03, propafenone, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propafenone.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Empagliflozin.]
[C07AA05, propranolol, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propranolol.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Epoprostenol is combined with Empagliflozin.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Empagliflozin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Aripiprazole.]
[P01BC01, quinine, Empagliflozin may increase the hypoglycemic activities of Quinine.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Empagliflozin.]
[C02AA01, rescinnamine, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Empagliflozin.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Empagliflozin.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Empagliflozin.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Empagliflozin.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Empagliflozin.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Empagliflozin.]
[C03DA01, spironolactone, Empagliflozin may increase the diuretic activities of Spironolactone.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Empagliflozin.]
